{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-26-000018","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.569842+00:00","generated_at":"2026-05-15T17:30:11.806293+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MacroGenics reports FY2025 net loss of $74.6M, cash $189.9M; pipeline data catalysts for 2026","bullets":["Net loss $74.6M in 2025 vs $66.9M in 2024; revenue flat at $149.5M; cash $189.9M down from $201.7M.","Phase 1 data for MGC026 (B7-H3 ADC) expected mid-2026; MGC028 (ADAM9 ADC) data in H2 2026.","LINNET study of lorigerlimab under partial clinical hold; update expected mid-2026. IND for MGC030 on track for Q3 2026.","Cash runway guidance extended into late 2027 based on current cash and partner payments.","R&D expenses down 17% to $147.2M; SG&A down 45% to $39.2M due to cost reductions."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-26-000018","json":"https://secwatch.observer/filing/0001125345-26-000018.json","markdown":"https://secwatch.observer/filing/0001125345-26-000018.md","text":"https://secwatch.observer/filing/0001125345-26-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534526000018/0001125345-26-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534526000018/mgnx-20260309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:30:11.806293+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f07287ba096a7c09f01cfa82c4e250230d7b7512","claim":"MACROGENICS INC reported the year ended December 31, 2025 results: revenue $149.5 million.","evidence_excerpt":"cash equivalents and marketable securities balance as of December 31, 2025, was $189.9 million, compared to $201.7 million as of December 31, 2024. • Revenue : Total revenue was $149.5 million for the year ended December 31, 2025, compared to $150.0 million for the year ended December 31, 2024. Total revenue included contract manufacturing revenue of $52.6 million for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534526000018/0001125345-26-000018-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Revenue","value":"$149.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}